Pharnext
SA (Paris:ALPHA) (FR0011191287 - ALPHA), a
biopharmaceutical company pioneering a new approach to the development
of innovative drug combinations based on big data genomics and
artificial intelligence, today announced that Rodolphe Hajj, Ph.D., the
Company’s Chief Pharmacology Officer, will present at the 8th
Annual Global Orphan Drug Conference.

Pharnext’s team will also attend the 2018 American Academy of
Neurology Annual Meeting as a first-time exhibitor (booth 908). The
meeting will take place on April 21-27, 2018 in Los Angeles, CA, U.S.

If you are interested in meeting the Pharnext management team during
these events, please send an email to contact@pharnext.com.

About Pharnext
Pharnext is an advanced clinical-stage
biopharmaceutical company developing novel therapeutics for orphan and
common neurodegenerative diseases that currently lack curative and/or
disease-modifying treatments. Pharnext has two lead products in clinical
development. PXT3003 is currently in an international Phase 3 trial for
the treatment of Charcot-Marie-Tooth disease 1A type and benefits from
orphan drug status in Europe and the United States. The results of this
trial are expected in the second half of 2018. PXT864 has generated
positive Phase 2 results in Alzheimer’s disease. Pharnext has developed
a new drug discovery paradigm based on big data genomics and artificial
intelligence: PLEOTHERAPY™. The Company identifies and develops synergic
combinations of drugs called PLEODRUG™ offering several key advantages:
efficacy, safety and robust intellectual property. The Company was
founded by renowned scientists and entrepreneurs including Professor
Daniel Cohen, a pioneer in modern genomics, and is supported by a
world-class scientific team.